Bntx stocks.

What this means: InvestorsObserver gives Biontech Se ADR (BNTX) an overall rank of 29, which is below average. Biontech Se ADR is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 29 means that 71% of stocks appear more favorable to our system.Find the latest Insider Activity data for BioNTech SE American Depositary Share (BNTX) at Nasdaq.com.Mar 23, 2023 · Plenty of stocks have been left behind and many carry outsize yields of 6% or more—including a total of about 40 in the S&P 500 and S&P MidCap 400 indexes, according to data from S&P Dow Jones ... The public float for BNTX is 237.70M, and currently, short sellers hold a 1.37% ratio of that floaft. The average trading volume of BNTX on November 23, 2023 was 669.58K shares. BNTX’s Market Performance. BNTX stock saw an increase of -2.73% in the past week, with a monthly gain of 2.25% and a quarterly increase of -17.72%.

Read more about BNTX’s peers. A high-level overview of BioNTech SE (BNTX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

BNTX Stock Assessment. Per Seeking Alpha, BioNTech's stock assessment reveals a mixed bag of results. In terms of valuation, the company is rated "A+" with forward-looking non-GAAP P/E at 20.76 ...How we approach editorial content. See the latest BioNTech SE ADR stock price (BNTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

BNTX Description — BioNTech SE. BioNTech develops immunotherapies for cancer and other diseases. Co.'s immunotherapy product candidates span the following four drug classes: messenger ribonucleic acid (mRNA) therapeutics, in which it is utilizing mRNA to deliver genetic information to cells; cell therapies, in which it is developing a range of cell …How we approach editorial content. See the latest BioNTech SE ADR stock price (BNTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.BioNTech Free Cash Flow Forecast for 2023 - 2025 - 2030. In the last three years, Free Cash Flow for BioNTech has grown by 5772.67%, going from $-237.10M to $13.45B. In the coming year, analysts are expecting an increase in Free Cash Flow, predicting it will reach $20.35B – an increase of 51.34%. Over the next eight years, experts anticipate ...Although shares of biotech company BioNTech ( BNTX -1.69%) have recently fallen along with most other stocks, the vaccine maker's performance over the past 12 months remains above that of the ...

BNTX - BioNTech SE Stock quote - CNNMoney.com Markets Tech Media Success Video BioNTech SE (NASDAQ:BNTX) 99.38 Delayed Data As of 3:59pm ET +1.08 / +1.10% Today’s Change 88.00 Today |||...

The analysts downgraded the stock to an Underweight rating from Neutral, with a price target of $99.00, down from the prior $106.00. J.P. Morgan notes the market's cautious stance on the company's ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), like BioNTech SE (NASDAQ:BNTX), and AbbVie Inc. (NYSE:ABBV), is a highly popular biotech stock today, as evidenced by the number of hedge funds ...Stock Price Forecast. The 16 analysts offering 12-month price forecasts for BioNTech SE have a median target of 124.69, with a high estimate of 264.82 and a low estimate of 98.75. The median ...Photo by Pascal Bernardon on Unsplash. Worst Performing NASDAQ Stocks In 2023 15. BioNTech SE (NASDAQ:BNTX) Number of Hedge Fund Holders: 22. YTD Share Price Decline as of July 30: 27.74%5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.BNTX stock YTD performance (as of 8 Sep 21). Despite the shared success in Comirnaty, only one of them, BioNTech, is the clear winner so far. Its YTD return raced to almost 450% in early August ...2 days ago

ALNY. Alnylam Pharmaceuticals Inc. 164.01. UNCH. UNCH. Get Moderna Inc (MRNA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Plenty of stocks have been left behind and many carry outsize yields of 6% or more—including a total of about 40 in the S&P 500 and S&P MidCap 400 indexes, according to data from S&P Dow Jones ...Dec 1, 2023 · BNTX Earnings Date and Information. BioNTech last issued its quarterly earnings results on November 6th, 2023. The reported $0.67 earnings per share for the quarter, topping the consensus estimate of ($0.59) by $1.26. The business earned $895.30 million during the quarter, compared to analyst estimates of $850.50 million. BNTX is a great stock. Anti-Vax and shorters may bring the stock down but can’t change the facts, revenue, profit and progress of this company. Watch it climbs in the long run.Oct 3, 2023 · BNTX’s price/forward earnings is 5.36. Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper ... BNTX | A complete BNTX overview by MarketWatch. View the latest market news and prices, and trading information.

Adobe Stock Forecast 12-08-2023. Forecast target price for 12-08-2023: $ 640.37. Positive dynamics for Adobe shares will prevail with possible volatility of 2.946%. Pessimistic target level: 632.88. Optimistic target level: 652.09.

Aug 7, 2023 · BNTX stock analysts projected a per-share loss of 30 cents. BioNTech blamed write-offs to partner Pfizer for the profit and sales hits. On today's stock market, BNTX stock toppled 7.5% to 98.50 ... Watching industrial stocks rise 500% above their bottom in 2009 was a real eye opener. After my master in molecular sciences, I did an MBA in management in 2010. During this studies I had courses ...View the latest BioNTech SE ADR (BNTX) stock price, news, historical charts, analyst ratings and financial information from WSJ.Spot Bitcoin ETF Hopes Lifted by SEC Move. Lucy Brewster | Nov 30, 2023. Our BNTX ETF report shows the ETFs with the most BNTX exposure, the top performing BNTX ETFs, and most popular BNTX ETF ...Coupang Inc. Last on the list, Coupang Inc. is a high-profile recent IPO stock to watch. It was the largest foreign company offering since Alibaba ( NYSE: BABA) came public in 2014. The South ...SIGA. SIGA Technologies, Inc. 5.64. +0.30. +5.62%. In this article, we will take a look at the 11 most undervalued biotech stocks to buy according to hedge funds. To see more such companies, go ...Biontech Se ADR stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... BNTX Stock Quotes API . BNTX Related ETF s. Symbol %Holdings 3M %Chg; BNTX -16.98% : Biontech Se ADR: IBB : 1.83% -5.91% : Nasdaq Biotechnology Ishares ETF: FBT : 3.55%Nov 24, 2023 · Complete BioNTech SE ADR stock information by Barron's. View real-time BNTX stock price and news, along with industry-best analysis. A high-level overview of BioNTech SE (BNTX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. BioNTech SE Sponsored ADR (BNTX) closed at $130.86 in the latest trading session, marking a -1.84% move from the prior day. This change lagged the S&P 500's daily gain of 0.31%. Meanwhile, the Dow ...

BioNTech SE - ADR Stock Chart and Share Price Forecast, Short-Term "BNTX" Stock Prediction for Next Days and Weeks Walletinvestor.com BioNTech SE - ADR (BNTX) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024

On today's stock market, BNTX stock dipped 0.4% and closed at 108.05. BNTX Stock: Lower Boosting Levels Expected. The Pfizer -partnered Covid shot is BioNTech's only commercial product. BioNTech's ...

BioNTech (NASDAQ: BNTX), a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock rally from about $80 at the end of 2020 to levels of almost $420 currently ...That comes out to about $9.97 and $4.61 billion, respectively. Both metrics topped BNTX stock analysts' forecasts, though earnings fell 24% and sales tumbled 23%.BioNTech SE ADR. An der Goldgrube 12. Mainz, Rheinland-Pfalz 55131. Phone 49 6131 908-40. Industry Biotechnology. Sector Health Care/Life Sciences. Fiscal Year-end 12/2023. Revenue $18.19B.The share price of BioNTech SE (BNTX) now. What analysts predict: $142.42. 52-week High/Low: $188.99 / $88. 50/200 Day Moving Average: $101.74 / $113.19. This figure corresponds to the Average Price over the previous 50/200 days. For BioNTech stocks, the 50-day moving average is the resistance level today.According to 13 stock analysts, the average 12-month stock price forecast for BioNTech SE stock is $146.46, which predicts an increase of 47.34%. The lowest target is $99 and the highest is $216. On average, analysts rate BioNTech SE stock as a buy.BNTX stock analysts projected a per-share loss of 30 cents. BioNTech blamed write-offs to partner Pfizer for the profit and sales hits. On today's stock market, BNTX stock toppled 7.5% to 98.50.US09075V1026. BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2 ...Within the last quarter, BioNTech (NASDAQ:BNTX) has observed the following analyst ratings: According to 6 analyst offering 12-month price targets in the last 3 months, BioNTech has an average ...Find the latest Exxon Mobil Corporation (XOM) stock quote, history, news and other vital information to help you with your stock trading and investing.As half of the duo behind one of the world's most widely used and effective COVID-19 vaccines, BioNTech (BNTX 1.37%) is well on its way to enduring stardom in the healthcare sector. Far from ...What this means: InvestorsObserver gives Biontech Se ADR (BNTX) an overall rank of 29, which is below average. Biontech Se ADR is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 29 means that 71% of stocks appear more favorable to our system.Jan 21, 2022 2:19AM EST. BioNTech stock (NASDAQ: BNTX), a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, declined by almost 31% over the last month, considerably ...

Pfizer (NYSE:PFE) and development partner BioNTech (NASDAQ:BNTX) announce a deal with the U.S. Department of Health and Human Services for up to 600M doses of their COVID-19 vaccine, currently ...Medical - Biomedical and Genetics. $23.493B. $18.242B. BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany. Stock Name. Country. Market Cap.What is the target price for BioNTech (BNTX) stock? The latest price target for BioNTech ( NASDAQ: BNTX) was reported by HC Wainwright & Co. on Tuesday, November 14, 2023. The analyst firm set a ...Instagram:https://instagram. verizon ratingsbest high yield reitsschwab private wealth servicesnysearca amlp Welcome to our investor page. Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid … fidelity day trading appbarron's dow jones Biotechs are becoming a dominating force in the healthcare sector. Some scientists believe that we’re in the “golden age” of biotechnology. 2021 was a difficult year for biotech stocks, generally, despite many of those trading at dirt-cheap valuations that don't even reflect the cash they have in hand. It was expected that Biotechs would perform5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. costco beats The European Patent Office declared a contested mRNA patent owned by Moderna invalid, the office said on Tuesday, handing a win to BioNTech and its partner Pfizer in a patent dispute between the two coronavirus vaccine makers. Moderna said in a statement that it disagreed with the office's decision and would lodge an appeal. 2. BioNTech. BioNTech has been one of the big winners in the coronavirus market. While its sales are dropping this year, its position in this space, financial situation, and pipeline look solid ...